Open AccessEffect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients With Septic Shock and Elevated Endotoxin Level
Author(s) -
R. Phillip Dellinger,
Sean M. Bagshaw,
Massimo Antonelli,
Debra Foster,
David J. Klein,
John C. Marshall,
Paul M. Palevsky,
Lawrence S. Weisberg,
Christa Schorr,
Stephen Trzeciak,
Paul M. Walker
Publication year - 2018
Publication title -
jama
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.688
H-Index - 680
eISSN - 1538-3598
pISSN - 0098-7484
DOI - 10.1001/jama.2018.14618
Subject(s) - hemoperfusion , medicine , septic shock , polymyxin b , polymyxin , randomized controlled trial , sepsis , sofa score , gastroenterology , antibiotics , hemodialysis , microbiology and biotechnology , biology
Polymyxin B hemoperfusion reduces blood endotoxin levels in sepsis. Endotoxin activity can be measured in blood with a rapid assay. Treating patients with septic shock and elevated endotoxin activity using polymyxin B hemoperfusion may improve clinical outcomes.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom